Validation of a manual protocol for BRAF V600E mutation-specific immunohistochemistry

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 5, 2015, Pages 382-388

  Dinges, Hanns C ^a   Capper, David ^b   Ritz, Olga ^a   Brüderlein, Silke ^a   Marienfeld, Ralf ^a   Von Deimling, Andreas ^b   Möller, Peter ^a   Lennerz, Jochen K ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

biomarker; BRAF antibody; hairy cell leukemia; melanoma

Indexed keywords

B RAF KINASE; ASPARTIC ACID; BRAF PROTEIN, HUMAN; FORMALDEHYDE; TUMOR MARKER; VALINE;

ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BREAST ADENOCARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FOLLICULAR CARCINOMA; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LANGERHANS CELL HISTIOCYTOSIS; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; MELANOMA; MUTATION RATE; NON SMALL CELL LUNG CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PYROSEQUENCING; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TISSUE FIXATION; UTERINE CERVIX CARCINOMA; GENE EXPRESSION; GENETICS; HISTOLOGY; LABORATORY AUTOMATION; LEUKEMIA, HAIRY CELL; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; STANDARDS; VALIDATION STUDY;

ASPARTIC ACID; AUTOMATION, LABORATORY; BIOMARKERS, TUMOR; DECALCIFICATION TECHNIQUE; DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, HAIRY CELL; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TISSUE EMBEDDING; TISSUE FIXATION; VALINE;

EID: 84929844198     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000092     Document Type: Article

References (35)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
2. Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert Rev Mol Diagn. 2012;12:127-138.
3. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013;19:4326-4334.
4. Millington GW. Mutations of the BRAF gene in human cancer, by Davies et al (Nature 2002; 417: 949-54). Clin Exp Dermatol. 2013; 38:222-223.
5. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-279.
6. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009;4:28-35.
7. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009;69:3042-3051.
8. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49:151-157.
9. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer. 2007;6:301-310.
10. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-2315.
11. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-1800.
12. Lennerz JK, Klaus BM, Marienfeld RB, et al. Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E. Br J Haematol. 2011;157:267-269.
13. Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7:e47054.
14. Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012; 106:123-129.
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
16. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
17. Dienstmann R, Tabernero J. BRAF as a target for cancer therapy. Anticancer Agents Med Chem. 2011;11:285-295.
18. Bösmüller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2012;44:329-335.
19. Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15:94-100.
20. Curry JL, Torres-Cabala CA, Tetzlaff MT, et al. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg. 2012;31:267-273.
21. Heinzerling L, Kuhnapfel S, Meckbach D, et al. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer. 2013;108:2164-2171.
22. Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2012;14:1-13.
23. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
24. Affolter K, Samowitz W, Tripp S, et al. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer. 2013;52:748-752.
25. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013;119:2765-2770.
26. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013;63:187-193.
27. Sperveslage J, Gierke M, Capper D, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol. 2013;125:911-912.
28. Mader A, Brüderlein S, Wegener S, et al. U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res. 2007;119:204-210.
29. Ritz O, Guiter C, Dorsch K, et al. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia. 2008;22:2106-2110.
30. Marin C, Beauchet A, Capper D, et al. Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med. 2013;138:71-75.
31. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2011;133:1624-1630.
32. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.
33. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18: 3242-3249.
34. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:1-3.
35. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120:e28-e34.